obtained a worldwide license for Hologic
, Invader plus, and real-time Invader detection chemistries for use in colorectal cancer
screening. The Invader chemistry is an accurate, easy-to-use, and rapid molecular detection platform that can be combined with PCR, according to Hologic. Exact anticipates coupling the digital PCR technology it has exclusively licensed from Johns Hopkins University with the quantitative detection capabilities of the Invader chemistry.
Exact states that this deal reinforces its stronghold in the stool-based DNA, or sDNA, screening market. The company’s IP portfolio now includes exclusive licenses to key detection technologies, sDNA testing methods, and important biomarkers, it adds.